conference on receptor tyrosine kinase quantiftation by ms2plex by x. morge - oncotrans 2017

7
Réf. General presentation - Confidential 1 - 06/02/2017 Receptor tyrosine kinase identification/quantification using LC/MSMS MS2plex applied to oncogenic recpetors

Upload: florence-fombertasse

Post on 20-Mar-2017

8 views

Category:

Health & Medicine


2 download

TRANSCRIPT

Page 1: Conference on Receptor Tyrosine kinase quantiftation by Ms2plex by X. Morge - Oncotrans 2017

Réf

. G

ener

al p

rese

ntat

ion

- C

onfid

entia

l

1 - 06/02/2017

Receptor tyrosine kinase identification/quantification using LC/MSMS MS2plex applied to oncogenic recpetors

Page 2: Conference on Receptor Tyrosine kinase quantiftation by Ms2plex by X. Morge - Oncotrans 2017

Réf

. G

ener

al p

rese

ntat

ion

- C

onfid

entia

l

2 - 06/02/2017

Rational for proteomic quantification (MS2plex®) in cancer management

Tumor heterogeneity is now well demonstrated and a critical issue (between/within patients)

This impairs the rational selection a therapeutic strategy

Identification of subtypes is achieved by Molecular Biology (not directly linked to protein expression/function) and through antibodies (with specificity and throughput issues)

MS2plex®, new alternative to allow the measurement of up to 21 different markers in a single run

Page 3: Conference on Receptor Tyrosine kinase quantiftation by Ms2plex by X. Morge - Oncotrans 2017

Réf

. G

ener

al p

rese

ntat

ion

- C

onfid

entia

l

3 - 06/02/2017

Proteomic quantification (MS2plex®*) principle

*Exclusive Technologie developed by Terasaki Tetsuya, Tohoku University, Sendai, Japan

Page 4: Conference on Receptor Tyrosine kinase quantiftation by Ms2plex by X. Morge - Oncotrans 2017

Réf

. G

ener

al p

rese

ntat

ion

- C

onfid

entia

l

4 - 06/02/2017

Membrane proteins in plasma membrane fraction expression levels of tumor tissues useful for an appropriate drug selection for the individual treatment of brain tumor

Patient having an anaplastic meningioma with metastatic lesion remaining after surgery & radiotherapy

* Platelet derived growth factor receptor

*

Biomarker applications: identifying accurate target receptor (clinical study case)

NeuropathologyandAppliedNeurobiology(2012),38,105–110

Page 5: Conference on Receptor Tyrosine kinase quantiftation by Ms2plex by X. Morge - Oncotrans 2017

Réf

. G

ener

al p

rese

ntat

ion

- C

onfid

entia

l

5 - 06/02/2017

Biomarker applications: identifying accurate target receptor (clinical study case)

Sunitinib (marketed as Sutent), an oral SMI of multi-targeted receptor tyrosine kinase approved for the treatment of renal cell carcinoma used as adjuvant chemotherapy

NeuropathologyandAppliedNeurobiology(2012),38,105–110

Page 6: Conference on Receptor Tyrosine kinase quantiftation by Ms2plex by X. Morge - Oncotrans 2017

Réf

. G

ener

al p

rese

ntat

ion

- C

onfid

entia

l

6 - 06/02/2017

Solutions

Central lab to quantify TKR & other membrane protein in your samples

Supplyer of kit ready-to-use

Prerequisits: mg of biopsis (frozen samples) Sensitivity in fmol range

Page 7: Conference on Receptor Tyrosine kinase quantiftation by Ms2plex by X. Morge - Oncotrans 2017

Thank you for your attention!

For additional details, we remain at your entire service

Take a chance to visit our website:

bertinpharma.com

Thank you for your attention!

For additional details, we remain at your entire service

Take a chance to visit our website: